← All trials
NCT05978492
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2023
- Primary completion
- Mar 31, 2025
- Completion date
- Aug 30, 2025
- First posted
- Aug 7, 2023
- Last posted
- Aug 28, 2023
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Txinno Bioscience Inc.Lead sponsor
- Seoul National UniversityOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.